Sun Pharma Advanced Research Co (NSE:SPARC) EV-to-OCF: (As of Aug. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:SPARC Sun Pharma Advanced Research Co Ltd NSE:SPARC
53 GF Score
Price ₹196.71
GF Value ₹4,399.47
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Sun Pharma Advanced Research Co EV-to-OCF?

EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Sun Pharma Advanced Research Co's Enterprise Value is ₹69,431 Mil. Sun Pharma Advanced Research Co's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was ₹0 Mil. Therefore, Sun Pharma Advanced Research Co's EV-to-OCF for today is .

The historical rank and industry rank for Sun Pharma Advanced Research Co's EV-to-OCF or its related term are showing as below:

NSE:SPARC' s EV-to-OCF Range Over the Past 10 Years
Min: -29.2   Med: 0   Max: -29.2
Current: -29.2

During the past 13 years, the highest EV-to-OCF of Sun Pharma Advanced Research Co was -29.20. The lowest was -29.20. And the median was .

NSE:SPARC's EV-to-OCF is ranked better than
90.25% of 1005 companies
in the Drug Manufacturers industry
Industry Median: 10.52 vs NSE:SPARC: -29.20

EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2026-08-22), Sun Pharma Advanced Research Co's stock price is ₹196.71. Sun Pharma Advanced Research Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was ₹48.810. Therefore, Sun Pharma Advanced Research Co's PE Ratio (TTM) for today is 4.03.


Sun Pharma Advanced Research Co  (NSE:SPARC) EV-to-OCF Explanation

EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Sun Pharma Advanced Research Co's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=196.71/48.810
=4.03

Sun Pharma Advanced Research Co's share price for today is ₹196.71.
Sun Pharma Advanced Research Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹48.810.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Sun Pharma Advanced Research Co EV-to-OCF Related Terms


Sun Pharma Advanced Research Co EV-to-OCF Historical Data

* Premium members only.

The historical data trend for Sun Pharma Advanced Research Co's EV-to-OCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sun Pharma Advanced Research Co EV-to-OCF Chart

Sun Pharma Advanced Research Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EV-to-OCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -39.08 -78.66 -27.74 -14.06 -17.91

Sun Pharma Advanced Research Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
EV-to-OCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 -17.91 0.00

NSE:SPARC vs ZTS: EV-to-OCF Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Sun Pharma Advanced Research Co's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sun Pharma Advanced Research Co EV-to-OCF vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sun Pharma Advanced Research Co's EV-to-OCF distribution charts can be found below:

* The bar in red indicates where Sun Pharma Advanced Research Co's EV-to-OCF falls into.


NSE:SPARC
53GF Score
Sun Pharma Advanced Research Co Ltd NSE:SPARC
EV-to-OCF is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sun Pharma Advanced Research Co EV-to-OCF Calculation

Sun Pharma Advanced Research Co's EV-to-OCF for today is calculated as:

EV-to-OCF=Enterprise Value (Today)/Cash Flow from Operations (TTM)
=69430.978/0
=

Sun Pharma Advanced Research Co's current Enterprise Value is ₹69,431 Mil.
Sun Pharma Advanced Research Co's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Is Sun Pharma Advanced Research Co (NSE:SPARC) Overvalued in 2026?

Based on GuruFocus' analysis, Sun Pharma Advanced Research Co stock appears to be undervalued. The current stock price of ₹196.71 is trading 95.5% below its estimated GF Value™ of ₹4,399.47. GuruFocus considers Sun Pharma Advanced Research Co to be Possible Value Trap.

Key valuation signals for NSE:SPARC:

  • EV-to-OCF:
  • GF Value™: ₹4,399.47 vs. price of ₹196.71 (95.5% below fair value)
  • GF Score™: 53/100 with 4 warning signs

No single metric tells the full story. See the NSE:SPARC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sun Pharma Advanced Research Co Business Description

Other Exchanges 532872:India
Address Off Mahakali Caves Road, 17-B, Mahal Industrial Estate, Andheri (East), Mumbai, MH, IND, 400093
Sun Pharma Advanced Research Co Ltd is an Indian specialty and generic drug manufacturing company. The company has identified pharmaceuticals research and development as its only reportable segment. The company is focused on drug discovery in focused therapy areas such as cancer and anti-inflammatory treatments. The company considers merger and acquisition investment as a potential component of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities. It derives maximum revenue from India and also has its presence in other countries.
53GF Score

Get the complete analysis for NSE:SPARC

EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹196.71
Price
₹4,399.47
GF Value